189224-48-4

189224-48-4 structure

Name: KU14R
Chemical Name: 2-(2-ethyl-3H-1-benzofuran-2-yl)-1H-imidazole
CAS Number: 189224-48-4
Molecular Formula: C₁₃H₁₄N₂O
Molecular Weight: 214.263
Catalog: Biochemical Inhibitor Protein tyrosine kinase
Create Date: 2016-07-22 20:21:44
Modify Date: 2024-01-08 17:53:59
KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.IC50 Value:Target: Insulin ReceptorA new I(3)-R antagonist, KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl)-2-imidazole), which selectively blocks the insulin secretory response to imidazolines. KU14R partially attenuated responses to Imidazole-4-acetic acid-ribotide (IAA-RP). The effects of KU14R on stimulus secretion-coupling in normal mouse islets and beta cells was compared by measuring KATP channel activity, plasma membrane potential, cytosolic calcium concentration ([Ca2+]c) and dynamic insulin secretion. In the presence of 10 mmol/l but not of 5 mmol/l glucose, KU14R (30, 100 or 300 micromol/l) was ineffective. KATP channel was blocked by KU14R (IC50 31.9 micromol/l, Hill slope -1.5). KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo.

Name	2-(2-ethyl-3H-1-benzofuran-2-yl)-1H-imidazole
Synonyms	cs-1007 1H-Imidazole, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)- hms3267m22 ku14r 2-(2-Ethyl-2,3-dihydro-1-benzofuran-2-yl)-1H-imidazole

Description	KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.IC50 Value:Target: Insulin ReceptorA new I(3)-R antagonist, KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl)-2-imidazole), which selectively blocks the insulin secretory response to imidazolines. KU14R partially attenuated responses to Imidazole-4-acetic acid-ribotide (IAA-RP). The effects of KU14R on stimulus secretion-coupling in normal mouse islets and beta cells was compared by measuring KATP channel activity, plasma membrane potential, cytosolic calcium concentration ([Ca2+]c) and dynamic insulin secretion. In the presence of 10 mmol/l but not of 5 mmol/l glucose, KU14R (30, 100 or 300 micromol/l) was ineffective. KATP channel was blocked by KU14R (IC50 31.9 micromol/l, Hill slope -1.5). KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo.
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Insulin Receptor Research Areas >> Metabolic Disease
References	[1]. Bozdagi O, Wang XB, Martinelli GP, et al. Imidazoleacetic acid-ribotide induces depression of synaptic responses in hippocampus through activation of imidazoline receptors. J Neurophysiol. 2011,105(3):1266-75. [2]. Bleck C, Wienbergen A, Rustenbeck I. Essential role of the imidazoline moiety in the insulinotropic effect but not the KATP channel-blocking effect of imidazolines; a comparison of the effects of efaroxan and its imidazole analogue, KU14R. Diabetologia. 2 [3]. Cooper EJ, Hudson AL, Parker CA, et al. Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans. Eur J Pharmacol. 2003;482(1-3):189-96. [4]. Mayer G, Taberner PV. Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Eur J Pharmacol. 2002;454(1):95-102. [5]. Susan L.F Chana, Anna L Palletta, John Clewsb. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with σ receptors. European Journal of Pharmacology. 1997,323( 2-3): 241-244.

Density	1.2±0.1 g/cm3
Boiling Point	428.1±34.0 °C at 760 mmHg
Melting Point	137-139ºC
Molecular Formula	C₁₃H₁₄N₂O
Molecular Weight	214.263
Flash Point	154.4±15.9 °C
Exact Mass	214.110611
PSA	37.91000
LogP	2.10
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.595
Storage condition	Store at RT

2171988-02-4	2171980-61-1
2171298-98-7	2227650-28-2
2172153-02-3	2172203-69-7
2172291-84-6	2171849-65-1
2171600-94-3	2172113-71-0